此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

治疗耐药性的 PET/CT 表征

2026年9月28日 更新者:University of Wisconsin, Madison

MCRPC 中 AR 靶向治疗耐药性的 PET/CT 表征

This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.

研究概览

详细说明

There are two groups, or cohorts, in this study. Participants are assigned to Cohort A if they have advanced prostate cancer and are scheduled to start a second-generation AR-targeted therapy (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed radiotherapy (e.g. Lu177-PSMA radio-ligand therapy. Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.

There are two medical imaging scans that will be done for research purposes in this study. One is called 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and the other is prostate-specific membrane antigen positron emission tomography (PSMA PET). These scans are done simultaneously with computed tomography (CT) scanning. Participants will be scheduled to have 6 scans, 3 FDG PET/CT scans and 3 PSMA PET/CT scans.

研究类型

介入性

注册 (估计的)

25

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Wisconsin
      • Madison、Wisconsin、美国、53705
        • 招聘中
        • University of Wisconsin
        • 接触:
        • 首席研究员:
          • John Floberg, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Histologically proven adenocarcinoma of the prostate.
  • At least 1 radiographic metastases as seen on conventional CT imaging or bone scan
  • Progressive prostate cancer as evident by at least two separate increase in PSA over nadir, and absolute PSA value at least 2 ng/ml (INTRINSIC RESISTANCE COHORT, ARSI patients ONLY)
  • Patients must be candidate for a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide), or Lu177-PSMA radioligand therapy (INTRINSIC RESISTANCE COHORT ONLY)
  • Men of age >18 years.
  • Patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging
  • Patients must be informed of the exploratory nature of the study and its potential risks, and must sign IRB-approved consent form indicating such understanding.
  • Life-expectancy at least 12 months
  • Patients currently receiving a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide) and must have had 1) PSA decline on treatment and 2) now have PSA increase over nadir while still on treatment (patients must be registered within 12 weeks of first documented PSA increase) (ACQUIRED RESISTANCE COHORT ONLY)

Exclusion Criteria:

  • Must not have uncontrolled diabetes (fasting blood sugar > 200 mg/dL or inability to safely hold diabetes medication or fast 6 hours prior to FDG PET scan)
  • Prior treatment with second-generation AR inhibitor for prostate cancer in the metastatic disease setting (prior second-generation AR inhibitor in the neoadjuvant or adjuvant setting is permitted unless patient developed progression while on treatment) (INTRINSIC RESISTANCE COHORT, AR-INHIBITOR GROUP ONLY)
  • Pain or clinical symptoms from metastatic prostate cancer requiring opioid analgesics
  • Known neuro-endocrine prostate cancer
  • Prior radioisotope therapy for castration-resistant prostate cancer
  • To avoid the possibility of unintended coercion, vulnerable populations such as incarcerated subjects, subjects unable to provide their own informed consent and non-English speaking patients will not be considered

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Intrinsic Resistance Cohort (Cohort A)

Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies .

Imaging scan

Imaging scan

其他:Acquired Resistance Cohort (Cohort B)

Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.

Imaging scan

Imaging scan

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Characterize intrinsic resistance based on FDG and PSMA PET through change in individual lesion update levels.
大体时间:Baseline to 12 weeks

Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which less activity is better.

Baseline to 12 weeks
Characterize change in intrinsic resistance based on FDG and PSMA PET.
大体时间:Baseline to 12 weeks

Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better.

Baseline to 12 weeks
Characterize change in intrinsic resistance based on FDG and PSMA PET.
大体时间:12 weeks to 36 weeks

Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better.

12 weeks to 36 weeks
Characterize change in intrinsic resistance based on FDG and PSMA PET.
大体时间:Baseline to 36 weeks

Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better.

Baseline to 36 weeks
Characterize acquired resistance at the time of progression
大体时间:Baseline to 36 weeks

Percentage and absolute changes in individual lesion update levels (ΔiSUVtotal) will be calculated.

Baseline to 36 weeks

次要结果测量

结果测量
措施说明
大体时间
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to PSA progression
大体时间:Baseline to 36 weeks

Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to PSA progression. PSA progression will be 25% increase and >2 ng/mL above PSA nadir

Baseline to 36 weeks
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression
大体时间:Baseline to 36 weeks

Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to radiographic progression. Time to radiographic progression will be defined as the number of days to confirmed radiographic progression using Prostate Cancer WorkingGroup 3 (PCWG3) criteria.

Baseline to 36 weeks
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time duration on treatment
大体时间:Up to 36 weeks

Analysis will be conducted to evaluate whether changes in lesion uptake values predict duration of treatment. Duration of treatment will be defined as the time from treatment start, to treatment discontinuation (and reason for discontinuation) using PCWG3 criteria.

Up to 36 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Glenn Liu, MD、University of Wisconsin, Madison
  • 首席研究员:Robert Jeraj, PhD、University of Wisconsin, Madison

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月6日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2022年12月6日

首先提交符合 QC 标准的

2022年12月6日

首次发布 (实际的)

2022年12月12日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2022-0910
  • A534260 (其他标识符:UW Madison)
  • 2022-0910 (其他标识符:UW Madison)
  • SMPH/MEDICINE/HEM-ONC (其他标识符:UW Madison)
  • NCI-2022-09580 (注册表标识符:NCI)
  • Protocol Version 8/1/2026 (其他标识符:UW Madison)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅